Phase 3 Study Comparing Belzupacap Sarotalocan Treatment to Sham Control for Small Choroidal Melanoma or Indeterminate Lesions

Program Overview

The main goal of this study is to see if belzupacap sarotalocan (bel-sar) is safe and works well for treating small choroidal melanoma or indeterminate lesions in the eye. The treatment involves injecting the bel-sar drug into the eye and activating it with a laser.

Description

This study is designed to test a new treatment called belzupacap sarotalocan (bel-sar) for people with small choroidal melanoma or indeterminate lesions in the eye. Participants will be randomly assigned to receive either the bel-sar treatment or a sham control, which means they will not receive the active treatment. The bel-sar treatment is given through an injection into the eye, specifically into the space behind the eye, using a special device. After the injection, a laser is used to activate the drug. The study is masked, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the sham control, to ensure unbiased results.

Eligibility Criteria

Locations